Skip to main content

KeyGene, Genalice Ink Licensing Deal

NEW YORK (GenomeWeb News) – Plant genomics firm KeyGene and startup bioinformatics company Genalice today announced a deal aimed at improving plant DNA analysis.

As part of the agreement, KeyGene will license Genalice MAP, a short-read alignment tool, which processes raw next-generation sequencing data into a small and easily manageable file for low-cost storage or further analysis.

"The breakthrough software solution … is a leap forward in improving our analysis pipeline and in staying ahead of competition," KeyGene CEO Arjen van Tunen said in a statement. "In addition, the strategic partnership with Genalice allows us to influence new functionalities within the product that will benefit our business."

Financial and other terms of the agreement were not disclosed.

Genalice is based in the Netherlands and launched late last year. Last month it said that it was awarded €200,000 ($275,000) for its participation in a European Union project to determine the causes of extreme aggressive behavior.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.